Central to this evolution has been the advent and integration of next-generation imaging technologies, most notably prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET–CT). PSMA PET–CT has set a new gold standard in staging accuracy by sensitively detecting metastatic deposits even at very low disease burden. This precision imaging is instrumental in delineating oligometastatic disease from widespread dissemination, thereby enabling clinicians to identify patients who could potentially benefit from aggressive local and metastasis-directed interventions. Such early and precise staging was unthinkable two decades ago and represents a quantum leap in prostate cancer diagnostics.

The therapeutic implications of detecting oligometastatic disease have been brought into sharp focus by evidence emerging from randomized phase II clinical trials. These studies have consistently demonstrated benefits associated with metastasis-directed therapy in patients who develop oligometastatic prostate cancer after initial treatment—a scenario known as metachronous disease. Metastasis-directed therapies, including stereotactic body radiotherapy and surgical resection of metastatic sites, have shown promising results in delaying disease progression and, in some cases, enhancing overall survival. These findings reinforce the paradigm where a subset of metastatic prostate cancer patients might achieve durable control through targeted approaches rather than systemic therapy alone.

Despite these encouraging results in the metachronous setting, the landscape is less defined for patients presenting with de novo oligometastatic prostate cancer—those found to have limited metastases at initial diagnosis. Early-phase trials suggest potential benefit from aggressive metastasis-directed therapies, yet the evidence base remains preliminary. Furthermore, this patient cohort is often subjected to intensified systemic treatments, such as androgen deprivation therapy combined with novel hormonal agents or chemotherapy, complicating the determination of the precise role and optimal timing of local and metastasis-directed interventions. The ongoing clinical trials aim to unravel these complexities to optimize individualized treatment strategies.

Alongside the focus on metastatic lesions, attention has increasingly turned to the primary tumor itself, resulting in growing interest in prostate-directed therapies for oligometastatic patients. Radiotherapy directed at the prostate gland and cytoreductive radical prostatectomy are being studied vigorously to understand their impact in the setting of systemic treatment intensification. These local therapies might not only reduce tumor burden but also modulate disease biology, improving systemic control. However, the integration of primary site treatment in the context of current systemic regimens remains an open question, underscoring the need for robust clinical data to ascertain the true benefit and refine patient selection criteria.

As research progresses, the oligometastatic paradigm is driving a more personalized approach to prostate cancer care, yet several key clinical and biological issues remain unresolved. One of the foremost challenges is the lack of a unified definition of oligometastatic prostate cancer. Variations exist in the number of metastatic sites considered compatible with this diagnosis, the timing of metastases appearance, and the imaging modalities used for detection. This heterogeneity not only impedes the standardization of treatment but also complicates trial design and the generalization of study outcomes across diverse patient populations and clinical settings.

Parallel to imaging and clinical criteria, the integration of biological markers and molecular profiling into patient selection is gaining momentum. Incorporating tumor genomics, microenvironmental factors, and systemic immune signatures could refine prognostication and therapy individualization, identifying which patients are most likely to benefit from local and metastasis-directed therapies. This biologically informed stratification could herald an era of precision oncology in oligometastatic prostate cancer, moving beyond conventional clinical staging into a realm where treatment decisions are guided by tumor biology and host response.

Another unsettled domain pertains to treatment sequencing. Clinicians face dilemmas regarding the optimal timing and combination of systemic therapies alongside local and metastasis-directed interventions. The duration of systemic therapy, its integration with focal treatments, and the potential synergistic effects of multimodal strategies require thorough examination within controlled clinical trials. Understanding these dynamics is critical, as improper sequencing or overtreatment could paradoxically undermine outcomes or exacerbate toxicity without yielding survival benefits.

Furthermore, consensus is lacking on the most appropriate clinical endpoints to assess treatment efficacy in oligometastatic prostate cancer. Traditional metrics such as overall survival and progression-free survival remain predominant; however, with the prospect of long-term disease control or delayed progression, novel endpoints reflecting quality of life, metastasis-free survival, and biomarker-driven response assessments are under deliberation. These metrics may offer more nuanced evaluations of therapeutic impact, particularly given the indolent or variable natural history of some oligometastatic presentations.

The scientific community’s growing attention on oligometastatic prostate cancer reflects striking progress but also signals complexity ahead. Establishing multidisciplinary task forces to harmonize definitions, incorporate biological sciences, and design rigorous clinical trials will be crucial to translating emerging insights into routine clinical practice. Collaborative efforts among urologists, oncologists, radiologists, pathologists, and translational researchers are imperative to drive innovation and optimize patient outcomes.

Patient selection for intensified localized and systemic treatment strategies remains an evolving science. As researchers continue to decipher the molecular and immunological underpinnings of oligometastatic disease, it becomes clear that a “one-size-fits-all” approach is inadequate. The heterogeneity observed suggests the existence of distinct biological subtypes within the oligometastatic population, each with differential therapeutic sensitivities and clinical trajectories. Unraveling these differences will require large-scale prospective molecular profiling coupled with clinical data integration.

Equally important is the ongoing development of advanced imaging techniques not just limited to PSMA PET–CT but incorporating functional and molecular imaging modalities. These tools promise to provide real-time insights into tumor metabolism, receptor expression patterns, and microenvironmental interactions, enhancing the precision of metastasis detection and monitoring treatment response. Such advances will facilitate adaptive therapeutic strategies tailored to the evolving disease landscape within individual patients.

The dynamic field of oligometastatic prostate cancer is a testimony to how shifting concepts in cancer biology and technological innovation can drive paradigm shifts in clinical oncology. The blurring lines between localized and metastatic disease demand a reconceptualization of therapeutic goals—from purely palliative to potentially curative or disease-controlling intentions in carefully selected patients. This shift is emblematic of the broader movement towards personalized medicine and adaptive treatment frameworks in oncology.

However, these exciting developments also raise important ethical and economic considerations. The high cost of advanced imaging, novel systemic agents, and specialized local treatments necessitates critical evaluation of cost-effectiveness and accessibility across diverse health care systems. Equitable delivery of these innovations requires policy frameworks that balance affordability with scientific progress and patient benefit.

In conclusion, the oligometastatic prostate cancer paradigm represents a frontier in cancer care, bridging previously discrete categories of disease in a manner that promises improved patient outcomes. While significant advances have been made in both diagnostics and therapeutics, many challenges persist. Continued multidisciplinary research, clinical innovation, and systematic evidence synthesis are essential to fully realize the potential of this evolving disease concept. As our understanding deepens, oligometastatic prostate cancer may well redefine the future trajectories of prostate cancer treatment and survivorship.

Subject of Research: Oligometastatic prostate cancer, focusing on diagnostic advancements, therapeutic paradigms, and clinical management strategies bridging localized and metastatic disease.

Article Title: Oligometastatic prostate cancer — bridging the gap between localized and metastatic disease.

Article References:
Giesen, A., den Hartog, J., Van Goubergen, J. et al. Oligometastatic prostate cancer — bridging the gap between localized and metastatic disease. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01144-9

Image Credits: AI Generated

Prostate-specific membrane antigen (PSMA) PET/CT is an imaging modality that leverages a radiolabeled molecule designed to bind selectively to prostate cancer cells. This molecular targeting causes cancerous tissues to “light up” on imaging scans, distinctly highlighting areas of aggressive disease that might warrant intervention. Unlike MRI, which assesses anatomical changes and abnormalities with variable specificity, PSMA PET/CT provides functional imaging that directly correlates with tumor biology, thus enabling more accurate identification of clinically significant cancers.

Typically, men at elevated risk of prostate cancer undergo MRI scans to pinpoint suspicious lesions within the prostate gland. Should the MRI produce inconclusive or equivocal findings—often categorized as PI-RADS scores 2 or 3—patients are traditionally subjected to biopsies, which involve sampling tissue to ascertain presence or absence of malignancy. While biopsies remain the definitive diagnostic standard, they pose various challenges including pain, infection risk, and considerable patient anxiety, compounded by the possibility of overdiagnosis and overtreatment of indolent lesions.

The PRIMARY2 trial strategically enrolled 660 high-risk individuals who had normal or non-suspicious MRI results but still faced uncertainty regarding their cancer status. Participants were randomized to receive either the standard biopsy or a PSMA PET/CT scan. The trial’s groundbreaking conclusion underscores that PSMA PET/CT imaging can identify those patients whose cancer risk is negligible or who harbor low-risk, slow-growing tumors unlikely to impact survival, thereby safely obviating the need for biopsy in roughly half of the cases.

For men whose PSMA PET/CT scans indicated the presence of suspicious disease, biopsies were then targeted precisely to areas highlighted by the imaging, enhancing the accuracy of tissue sampling and reducing the likelihood of false-negative results. This targeted approach not only optimizes diagnostic yield but concurrently minimizes procedure-related morbidity by sparing patients unnecessary tissue trauma in non-suspicious regions.

This novel imaging protocol, therefore, simultaneously tackles two major clinical challenges: it reduces unnecessary biopsies that expose patients to potential complications and distress, and critically, it avoids missing clinically significant prostate cancers that require prompt treatment. The ability of PSMA PET/CT to discriminate aggressive disease is attributable to its high sensitivity and specificity that exceed those of traditional MRI, especially in the subset of men with ambiguous MRI findings.

The trial’s outcomes hold considerable clinical significance because overdiagnosis and overtreatment are recognized issues in prostate cancer management. Many tumors detected on biopsy are indolent and would not progress to cause symptoms or threaten life, hence avoiding unnecessary biopsy procedures conserves healthcare resources and spares patients from unwarranted intervention.

Beyond diagnostic refinement, PSMA PET/CT imaging also has potential implications for personalized treatment planning. By delineating the spatial distribution of cancer within the prostate and detecting metastases not visible on MRI, clinicians can tailor therapeutic strategies more precisely, including decisions around active surveillance, focal therapies, or more aggressive treatment modalities.

The PRIMARY2 study is a multicenter, phase III randomized controlled trial coordinated across Australia, led by Peter MacCallum Cancer Centre and St Vincent’s Hospital in Sydney. The trial’s robust design and substantial cohort confer high validity to its findings. Moreover, PSMA PET/CT technology is becoming more accessible globally, although cost and infrastructure needs currently limit widespread adoption outside regions like Australia.

Experts in the field have lauded the trial’s methodology and impact. Dr. James Buteau, a nuclear medicine physician involved in the study, emphasized how the unparalleled imaging contrast achieved with PSMA PET/CT could revolutionize clinical workflows by mitigating the longstanding problem of prostate cancer overdiagnosis. Meanwhile, co-lead Professor Louise Emmett highlighted the profound psychological relief provided to patients through more definitive non-invasive risk stratification.

International perspectives from urologists at the European Association of Urology validate the trial’s findings as a critical step forward. Professor Derya Tilki from Germany praised the clear clinical benefit of incorporating PSMA PET/CT in the diagnostic algorithm for patients with low to intermediate MRI risk lesions, underscoring the balance between reducing unnecessary biopsies and maintaining accurate detection of significant cancers.

Future directions for research include longer-term follow-up of the PRIMARY2 cohort to confirm durability of outcomes and to validate cancer-specific survival benefits. Additionally, expanding accessibility to PSMA PET/CT and integrating it with emerging biomarkers and artificial intelligence could further enhance cancer diagnostics and personalized care.

In summary, the PRIMARY2 trial provides compelling evidence that PSMA PET/CT imaging, as an adjunct to standard MRI, refines prostate cancer detection by selectively identifying men who require biopsy and sparing those with indolent disease from invasive procedures. This innovation holds transformative potential for patient-centered care, reducing physical and psychological burdens while improving clinical decision-making in prostate cancer management.

Subject of Research: People

Article Title: PSMA PET/CT Imaging Halves Need for Prostate Biopsy While Enhancing Cancer Detection: PRIMARY2 Trial Findings

News Publication Date: 13 March 2026

Image Credits: PRIMARY2 trial

Keywords: Prostate cancer, Medical imaging, Diagnostic imaging, Positron emission tomography, Diagnostic accuracy, False positives, Clinical trials, Medical diagnosis, Medical tests, Cancer screening, Oncology, Cancer risk, Cancer patients, Tumor growth, Malignant transformation, Urology

Prostate cancer recurrence represents a formidable challenge in oncology, particularly affecting 20% to 40% of patients within a decade following prostatectomy for localized disease. Detecting this recurrence early, often signaled by a rising prostate-specific antigen (PSA) level, is crucial for improving prognosis. However, conventional imaging modalities such as bone scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) are frequently inadequate at identifying low-volume, early recurrent disease when PSA levels remain low. This diagnostic limitation traditionally compels clinicians to adopt broad treatment approaches, encompassing the prostate bed and adjacent lymph nodes, often subjecting patients to potentially unnecessary radiation exposure and systemic therapy.

The advent of PSMA PET/CT scanning marks a sophisticated leap forward in oncologic imaging technology. By leveraging a radiotracer specifically targeting the prostate-specific membrane antigen—a transmembrane protein ubiquitously overexpressed on prostate cancer cells—this technique exquisitely delineates metastatic deposits with unprecedented sensitivity and specificity. PSMA PET/CT surpasses conventional imaging by unveiling micrometastases and subtle disease foci undetectable by standard modalities. Such granular visualization fundamentally alters clinical decision-making, enabling oncologists to tailor radiation fields and systemic therapies based on precise tumor localization and extent.

The UCLA study meticulously tracked 113 men exhibiting biochemical recurrence post-prostatectomy, all subjected to PSMA PET/CT imaging before salvage radiation therapy. Patient management was individualized based on scan findings, encompassing decisions on expanding radiation fields to include the entire pelvis, administering androgen deprivation therapy (ADT) for nodal or distant metastases, and intensifying radiation doses to visually identified tumor sites. This comprehensive approach integrated advanced imaging insights to optimize oncologic control while mitigating side effects.

Outcomes monitored over a median duration of five years disclosed a striking benefit for patients whose imaging identified residual disease localized within the prostate bed or pelvic lymph nodes. In these cases, whole-pelvis radiotherapy yielded superior control compared to prostate bed-only treatment, underscoring the necessity of encompassing regional nodal basins harboring occult metastases. Moreover, subjects with PSMA PET/CT evidence of nodal or distant metastatic dissemination derived significant survival advantage when ADT accompanied radiation, highlighting the importance of multimodal systemic intervention in managing disseminated microscopic disease.

Intriguingly, patients whose PSMA PET/CT scans revealed no discernible disease fared best overall, suggesting that early salvage radiation targeted to the prostate bed alone remains highly efficacious in truly localized biochemical failure. This discovery emphasizes the critical role of PET/CT imaging in sparing patients from the added morbidity of expanded radiation fields or hormone therapy when unwarranted, ultimately improving quality of life.

The five-year survival outcomes are notable, with nearly all patients alive and 72% remaining free of distant metastatic progression. Such data affirm the prognostic power of PSMA PET/CT-guided therapy and bolster its integration into salvage treatment algorithms. Dr. Jeremie Calais, the study’s senior author and director of clinical research in UCLA’s Department of Nuclear Medicine and Theranostics, remarks that this precision imaging shields patients from the “one-size-fits-all” radiation paradigm, ushering in personalized oncologic strategies that carefully balance efficacy and adverse effects.

From a mechanistic perspective, PSMA-targeted PET imaging exploits the biological affinity of radiolabeled ligands to PSMA—a glutamate carboxypeptidase highly expressed on prostate cancer cells but with limited expression in normal tissues. This molecular specificity translates into high contrast images where even micro-metastases can be confidently localized. The radiotracer’s rapid clearance from non-target tissue further enhances visualization clarity, facilitating accurate assessment of tumor burden and distribution.

This study challenges conventional reliance on serum PSA levels alone as the determinant for initiating salvage therapies. Remarkably, traditional PSA metrics correlated poorly with long-term clinical outcomes, underscoring the critical need for imaging-based assessment tools that reflect true disease status. Dr. John Nikitas, first author and radiation oncology resident at UCLA Health, emphasizes that integrating PSMA PET/CT findings into clinical guidelines will profoundly refine therapeutic choices, advocating for imaging-informed rather than PSA-driven treatment stratification.

The implications for clinical practice are profound: men presenting with recurrent prostate cancer can now expect a more nuanced evaluation, wherein management strategies are intricately tailored to their individualized disease patterns. Patients exhibiting localized recurrences may therefore avoid overtreatment and its associated morbidities, whereas those with advanced metastatic spread stand to benefit from intensified multimodal therapy regimens specifically directed at eradicating visible disease sites.

This research represents a collaborative milestone achieved through the dedicated efforts of a multidisciplinary UCLA team, including experts in nuclear medicine, radiation oncology, medical oncology, and molecular imaging. Beyond its immediate clinical impact, the study also stimulates further inquiry into the optimization of PSMA PET/CT protocols, the potential integration with novel systemic agents, and the utility of this imaging modality in other stages of prostate cancer management.

As PSMA PET/CT technology becomes more widely accessible and incorporated into clinical workflows, it holds the promise not only to elevate prostate cancer care but also to serve as a template for precision medicine applications across diverse oncologic domains. Furthermore, its capacity to prevent unnecessary treatment-related toxicity while maintaining or enhancing survival outcomes heralds a new era of patient-centered cancer therapy.

In conclusion, this landmark investigation affirms PSMA PET/CT as an indispensable tool for the personalized management of recurrent prostate cancer post-surgery. It empowers physicians with detailed anatomical and biological insights, enabling the delivery of targeted radiotherapy and informed use of hormone therapy that collectively improve long-term survival and quality of life for patients facing this complex clinical scenario. The convergence of advanced molecular imaging and tailored treatment protocols exemplifies the future frontier of cancer care—where precision diagnostics drive individualized therapeutic excellence.

Subject of Research: Prostate cancer recurrence and the application of PSMA PET/CT imaging for personalized salvage radiotherapy.

Article Title: Precision Imaging with PSMA PET/CT Enhances Salvage Radiotherapy Outcomes in Recurrent Prostate Cancer: A Five-Year Retrospective Study.

News Publication Date: Not specified.

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• Journal of the National Comprehensive Cancer Network (DOI link): https://doi.org/10.6004/jnccn.2025.7102

References:

• Study authors including Dr. Jeremie Calais, Dr. John Nikitas, et al.
• Published in the Journal of the National Comprehensive Cancer Network.

Keywords: Prostate cancer, cancer recurrence, PSMA PET/CT, molecular imaging, radiation therapy, androgen deprivation therapy, salvage radiotherapy, advanced diagnostics, precision oncology, medical imaging, nuclear medicine, prostate-specific membrane antigen.

Prostate cancer, one of the most prevalent malignancies among men globally, frequently resurfaces following radical prostatectomy. Biochemical recurrence, characterized by rising prostate-specific antigen (PSA) levels, poses a significant clinical challenge, occurring in approximately 40% of patients post-surgery. Traditional imaging modalities such as bone scintigraphy, CT, and MRI have historically been used to localize such recurrences, guiding salvage radiotherapy interventions aimed at eradicating residual disease. However, these methods often lack the sensitivity necessary to detect early metastatic or locoregional recurrence.

PSMA PET/CT—prostate-specific membrane antigen positron emission tomography/computed tomography—has emerged as a cutting-edge diagnostic technique, offering unparalleled sensitivity and specificity in visualizing prostate cancer lesions at low PSA levels. PSMA, a transmembrane protein highly expressed in prostate cancer cells, serves as a target for radiotracers that illuminate cancerous tissue during PET imaging. This capability facilitates precise anatomical localization, enabling clinicians to tailor salvage radiotherapy plans with greater accuracy than was previously achievable.

Despite the widespread acceptance of PSMA PET/CT for enhancing diagnostic clarity, until now, the critical question remained: does employing PSMA PET/CT prior to salvage radiotherapy translate into concrete survival benefits? Addressing this knowledge gap, lead researcher Anna W. Mogensen and colleagues at Aalborg University Hospital leveraged Denmark’s comprehensive, nationwide health registries to conduct an observational cohort study involving 844 patients treated with salvage radiotherapy between 2015 and 2023.

The cohort was bifurcated into two groups; 308 patients underwent pretreatment PSMA PET/CT imaging, while 536 patients did not. Rigorous statistical analyses assessed overall survival and biochemical recurrence-free survival outcomes over a follow-up period extending to five years post-therapy. The study utilized robust endpoints, including one-, two-, and five-year survival metrics, to ascertain the clinical impact of PSMA PET/CT-guided interventions.

Remarkably, the analysis revealed that patients receiving PSMA PET/CT prior to salvage radiotherapy demonstrated significantly higher survival rates. Specifically, the one-year survival rate for the PSMA PET/CT group reached 100%, slightly edging the 99% observed in the non-PSMA group. More importantly, at two years, survival was 99.5% versus 97.8%, and at five years, 98.1% compared to 93.8%, respectively. These survival advantages underscore the prognostic value of incorporating molecular imaging into therapy decision-making for recurrent prostate cancer.

Moreover, biochemical recurrence-free survival at three years further corroborated these findings: 74.9% for patients who underwent PSMA PET/CT versus 69.4% in the comparison group. Biochemical recurrence-free survival is a crucial prognostic indicator, reflecting successful suppression of cancer activity following treatment. These data collectively suggest that PSMA PET/CT not only guides more effective salvage radiotherapy planning but also contributes meaningfully to long-term disease control.

The implications of these results extend beyond survival statistics, emphasizing a paradigm shift in oncologic care. By providing refined visualization of recurrent cancer loci, PSMA PET/CT empowers clinicians to select patients who are most likely to benefit from salvage radiotherapy, thereby sparing others from potentially unnecessary or ineffective treatment. This tailored therapeutic approach aligns with the principles of precision medicine, aiming to optimize clinical outcomes while minimizing adverse effects and healthcare costs.

Anna W. Mogensen highlights that PSMA PET/CT was incrementally implemented across Danish regions beginning in 2015, creating a natural experiment environment whereby comparative outcome analysis became viable. This staggered adoption allowed researchers to draw inference from real-world data, reflecting routine clinical practices rather than controlled clinical trial settings. Consequently, the study’s findings hold significant external validity and relevance for broader healthcare systems contemplating integration of PSMA PET/CT imaging.

From a technical perspective, PSMA PET/CT combines the anatomical resolution of computed tomography with the functional imaging capabilities of positron emission tomography. Radiolabeled ligands targeting PSMA bind selectively to prostate cancer cells, emitting positrons detectable by the PET scanner. This fusion imaging technique detects both soft tissue and bone metastases with high precision, often revealing sites of spread previously occult to conventional imaging. As a result, radiation oncologists can deliver high-dose radiotherapy to defined targets while sparing healthy tissues, potentially improving therapeutic indices.

The study capitalizes on Denmark’s well-established national health registries, renowned for their comprehensive and longitudinal data capture. Such resources enabled investigators to track patient demographics, treatment modalities, imaging utilization, and survival outcomes over extensive periods. This population-level approach provides critical insights unattainable via smaller-scale studies, reinforcing the robustness and generalizability of conclusions pertaining to PSMA PET/CT’s clinical utility.

Importantly, the findings suggest that early incorporation of PSMA PET/CT into the diagnostic workflow for biochemically recurrent prostate cancer could become a new standard in oncology practice worldwide. As molecular imaging technologies continue to evolve, integrating these tools prospectively within treatment algorithms promises to enhance personalized cancer management, ultimately improving survival and quality of life for patients.

The authors of this impactful study represent a multidisciplinary team from several Danish institutions, including Aalborg University Hospital and Aarhus University Hospital, combining expertise in nuclear medicine, clinical epidemiology, oncology, and clinical cancer research. Their collaboration exemplifies the critical intersection of cutting-edge imaging, epidemiological rigor, and clinical oncology needed to drive innovation in cancer care.

In conclusion, this comprehensive real-world study confirms that pretreatment PSMA PET/CT significantly improves overall survival outcomes in men with biochemically recurrent prostate cancer undergoing salvage radiotherapy. These results not only affirm the diagnostic superiority of PSMA PET/CT but also establish its vital role in optimizing therapeutic strategies. As clinicians and health systems worldwide grapple with the challenges of recurrent prostate cancer management, this evidence strongly advocates for the widespread adoption of PSMA PET/CT to guide salvage treatment and improve patient prognoses.

Subject of Research: The impact of PSMA PET/CT imaging on survival outcomes in men with biochemically recurrent prostate cancer treated with salvage radiotherapy.

Article Title: The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country

News Publication Date: August 13, 2025

Web References:

• Journal of Nuclear Medicine
• DOI link

Image Credits: Image created by HD Zacho and AW Mogensen et al., Aalborg University Hospital, Aalborg, Denmark.

Keywords: Molecular imaging, Medical imaging, Positron emission tomography, Prostate cancer